Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Wix.Com Ltd — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while Wix.Com Ltd trades at $68.86 (market cap $2.79B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 10.6× Wix.Com Ltd's market cap, and Wix.Com Ltd is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | WIX | |
|---|---|---|
Market Cap | $29.60B | $2.79B |
Sector | Health | Technology |
52-Week High | $491.22 | $184.24 |
52-Week Low | $205.48 | $40.43 |
Enterprise Value | $27.56B | $3.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
WIX stock trades at $68.78, up 10.18% today, with a bullish technical signal from moving averages. Revenue grew to $1.99B in 2025, but net income margin remains negative at -8.19%, and the company faces a securities class action. The P/E ratio is elevated at 62.84, indicating high growth expectations. Recent news highlights the launch of Symphony by Wix, an AI system for SMBs, amidst legal challenges.
The outlook is mixed: strong analyst consensus (65.85% buy rating) and a $79.75 price target suggest upside, but legal risks and negative cash flow in 2025 pose significant headwinds. Investors should weigh growth potential against execution and litigation risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
